To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America at the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY). Spokesperson Jim Baker said avapritinib would be Blueprint's first commercial launch.

Avapritinib is an inhibitor of stem cell factor receptor tyrosine kinase

Read the full 650 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers